MCID: PLM035
MIFTS: 40

Pulmonary Eosinophilia malady

Categories: Respiratory diseases, Blood diseases

Aliases & Classifications for Pulmonary Eosinophilia

About this section

Aliases & Descriptions for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 10 47 12 65
 
Asthmatic Pulmonary Eosinophilia 65

Classifications:



External Ids:

Disease Ontology10 DOID:9498
ICD9CM29 518.3
MeSH36 D011657
ICD1027 J82
UMLS65 C0034068, C0340076

Summaries for Pulmonary Eosinophilia

About this section
MalaCards based summary: Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to loeffler syndrome and chronic eosinophilic pneumonia. An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways are CXCR3-mediated signaling events and Inflammatory Response Pathway. Affiliated tissues include lung, t cells and breast, and related mouse phenotypes are respiratory system and hematopoietic system.

Related Diseases for Pulmonary Eosinophilia

About this section

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 291)
idRelated DiseaseScoreTop Affiliating Genes
1loeffler syndrome32.9CCL11, CSF2, IL5, RNASE3
2chronic eosinophilic pneumonia30.9CCL11, CSF2, EPX, IL13, IL4, IL5
3capillary hemangioma29.5CCL11, IL13, IL4, IL5
4malaria29.3CCL11, CSF2, IL13, IL4, IL5
5asthma27.6CCL11, CCR3, CSF2, CYSLTR1, EPX, IL13
6eosinophilic pneumonia12.0
7carrington syndrome11.9
8idiopathic acute eosinophilic pneumonia10.5
9trabecular follicular adenocarcinoma10.4IL5, RNASE3
10blepharophimosis10.3CCL11, IL5
11cholesteatoma of attic10.3CCL11, IL5
12lattice corneal dystrophy10.3CSF2, IL5
13pars planitis10.3IL13, IL5
14keratoconjunctivitis10.3IL5, RNASE3
15non specific chronic endometritis10.3IL5, RNASE3
16egg allergy10.2IL4, RNASE3
17endotheliitis10.2
18papillary conjunctivitis10.2CCL11, IL5, RNASE3
19bacterial gastritis10.2CCL11, IL5, RNASE3
20limbic encephalitis with ncmags antibodies10.2IL4, IL5
21gonococcal bursitis10.2IL4, IL5
22giant papillary conjunctivitis10.2CCL11, IL4
23idiopathic interstitial pneumonia10.2IL4, IL5
24winchester syndrome10.2EPX, RNASE3
25balkan nephropathy10.2CCL11, IL5, RNASE3
26antley-bixler syndrome with genital anomalies and disordered steroidogenesis10.2CCL11, IL13, IL5
27juvenile dermatitis herpetiformis10.2CCL11, IL5, RNASE3
28mixed extragonadal germ cell cancer10.2EPX, RNASE3
29verrucous nevus acanthokeratolytic10.2CCL11, IL13, RNASE3
30penicillin allergy10.2IL13, IL4
31central nervous system childhood germ cell tumor10.1CCL11, IL13, IL5
32postmenopausal atrophic vaginitis10.1CCL11, IL13, IL5
33mobitz type ii atrioventricular block10.1IL4, IL5
34schizophrenia10.1
35hepatitis10.1
36adenocarcinoma10.1
37adenoma10.1
38steatorrhea10.1CSF2, IL13, IL5
39skin conditions10.1CYSLTR1, IL5, RNASE3
40extrapulmonary tuberculosis10.1IL13, IL4
41kyphoscoliotic heart disease10.1IL4, IL5, RNASE3
42status asthmaticus10.1IL4, IL5, RNASE3
43granulomatous amebic encephalitis10.1IL4, IL5
44hypertensive encephalopathy10.1CCL11, IL4
45anterior dislocation of lens10.1CCL11, IL4, RNASE3
46hepatitis e10.1CCL11, IL4, IL5
47leukemia10.1
48prostatitis10.1
49neuronitis10.1
50hypoxia10.1

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to pulmonary eosinophilia

Symptoms for Pulmonary Eosinophilia

About this section

Drugs & Therapeutics for Pulmonary Eosinophilia

About this section

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 97)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Nitric OxideapprovedPhase 4, Phase 256410102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
Inomax
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
2
PrednisoloneapprovedPhase 4108250-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
Flo-pred
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
MLS001304083
 
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
Millipred
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Omnipred
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
3
MethylprednisoloneapprovedPhase 4108283-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
A-methapred
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Depo-medrol
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Solu-medrol
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
4
Omalizumabapproved, investigationalPhase 4137242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
5
Ciclesonideapproved, investigationalPhase 474141845-82-1444033
Synonyms:
(R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
126544-47-6
141845-82-1
AC-1330
Alvesco
Alvesco (TN)
Alvesco HFA
B-9207-015
BTR-15
BTR-15K
BY-9010
BYK-20426
CID6918155
Ciclesonide
 
Ciclesonide (JAN/USAN/INN)
Ciclesonide [INN]
D01703
KS-1165
LS-186047
MolPort-005-940-705
NCGC00167972-01
Omnair
Omnaris
Omnaris HFA
Osonase
Osonide
RPR 251526
TBN-15
UNII-S59502J185
Zetonna
6
BudesonideapprovedPhase 438151333-22-363006, 5281004
Synonyms:
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC-4697
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
B 7777
B7777_SIGMA
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Bidien
Bio-0010
Budecort Inhaler
Budenofalk
Budeson
Budesonide
Budesonide (JAN/USAN/INN)
Budesonide Easyhaler
Budesonide Inhalation
Budesonide MMX
Budesonide Nasal
Budesonide [USAN:INN:BAN:JAN]
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
CPD000058337
Cortivent
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
EU-0100174
Entocort
Entocort EC
Entocort EC (TN)
Giona Easyhaler
HMS1569H17
HMS1921I22
HMS2094I13
HMS501H17
 
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
LS-187734
LS-7235
Lopac0_000174
MAP-0010
MLS000028507
MLS001077323
MLS002207112
Micronyl
Miflonide
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Prestwick_840
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort FLEXHALER
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort Turbuhaler
Pulmicort turbuhaler
Respules
Rhinocort
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort alpha
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S-1320
S1286_Selleck
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
ST51039033
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Uceris
Unit dose budesonide
ZINC03938751
ZINC04097286
budesonide
7
MontelukastapprovedPhase 4264158966-92-85281040
Synonyms:
(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
(R-(e))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1e)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
151767-02-1 (sodium)
158966-92-8
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
AC1NQXXW
Apxi toxin
BIDD:GT0394
Brondilat
Brondilat (TN)
C07482
C35H36ClNO3S
CHEBI:50730
CHEMBL787
CID5281040
D08229
 
DB00471
HMS2089D07
HSDB 7582
LS-173539
MK 0476
MK-0476
Montair
Montelukast
Montelukast (INN)
Montelukast Sodium
Montelukast [INN:BAN]
Montelukast sodium
Montelukastum
Montélukast
Singulair
Singular
UNII-MHM278SD3E
montelukast
sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
8Adrenergic beta-2 Receptor AgonistsPhase 4, Phase 2741
9Adrenergic beta-AgonistsPhase 4, Phase 21266
10Adrenergic AgonistsPhase 4, Phase 22331
11Adrenergic AgentsPhase 4, Phase 24204
12Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
13Respiratory System AgentsPhase 4, Phase 23931
14Bronchodilator AgentsPhase 4, Phase 22377
15Fluticasone Propionate, Salmeterol Xinafoate Drug CombinationPhase 4, Phase 2136
16
Salmeterol xinafoatePhase 4, Phase 232694749-08-356801
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
 
GR-33343 G
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
SMR000875207
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent Inhaler and Disks
Serevent diskus
UNII-6EW8Q962A5
Ultrabeta
salmeterol xinafoate
17Antibodies, MonoclonalPhase 4, Phase 3, Phase 22413
18
FluticasonePhase 4, Phase 258990566-53-3, 80474-14-262924, 22833648
Synonyms:
90566-53-3
AC-456
AC1NSJZT
Asmatil
Axotide
BIDD:GT0819
Brethal
C07815
CHEMBL1201396
CID5311101
Cultivate
Cutivate
D07981
Flixonase
Flixonase Nasal Spray
Flixotide
Flixotide Disk
 
Flixotide Disks
Flixotide Inhaler
Flonase
Flovent
Flovent Diskus
Flovent Rotadisk
Fluinol
Flunase
Flusonal
Fluspiral
Fluticaps
Fluticaps (TN)
Fluticasone (INN)
Fluticasonpropionat Allen
Flutide
Flutivate
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
fluticasone
19Dermatologic AgentsPhase 4, Phase 24555
20AntiemeticsPhase 43213
21Neurotransmitter AgentsPhase 4, Phase 214795
22Tocolytic AgentsPhase 4, Phase 2561
23AlbuterolPhase 4, Phase 2384
24ImmunoglobulinsPhase 4, Phase 3, Phase 24477
25Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 38478
26AntibodiesPhase 4, Phase 3, Phase 24477
27Methylprednisolone acetatePhase 41082
28Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 34256
29Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 39988
30Gastrointestinal AgentsPhase 46401
31Hormone AntagonistsPhase 4, Phase 2, Phase 310002
32HormonesPhase 4, Phase 2, Phase 311748
33glucocorticoidsPhase 4, Phase 2, Phase 33896
34Methylprednisolone HemisuccinatePhase 41082
35Protective AgentsPhase 4, Phase 2, Phase 15651
36Anti-Allergic AgentsPhase 4, Phase 21312
37Anti-Asthmatic AgentsPhase 4, Phase 22796
38Neuroprotective AgentsPhase 41376
39Prednisolone phosphatePhase 41082
40Peripheral Nervous System AgentsPhase 4, Phase 218510
41Prednisolone acetatePhase 41082
42Prednisolone hemisuccinatePhase 41082
43Tiotropium BromidePhase 4311
44BromidesPhase 4523
45Cholinergic AgentsPhase 43243
46Cholinergic AntagonistsPhase 41423
47Muscarinic AntagonistsPhase 4961
48ParasympatholyticsPhase 4902
49Leukotriene AntagonistsPhase 4270
50Contraceptives, OralPhase 43734

Interventional clinical trials:

(show all 50)
idNameStatusNCT IDPhase
1The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic PneumoniaCompletedNCT00632554Phase 4
2Small Particle Steroids in Refractory AsthmaCompletedNCT01171365Phase 4
3Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsCompletedNCT00670930Phase 4
4Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsRecruitingNCT02654145Phase 4
5Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMAActive, not recruitingNCT02546349Phase 4
6Effect of Xolair on Airway HyperresponsivenessActive, not recruitingNCT00208234Phase 4
7Efficacy and Safety of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic BronchitisNot yet recruitingNCT01121016Phase 4
8A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaCompletedNCT01285323Phase 3
9A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01270464Phase 3
10A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01287039Phase 3
11Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaCompletedNCT01508936Phase 3
12Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)CompletedNCT00647166Phase 3
13Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY StudyRecruitingNCT02594332Phase 3
14Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma PatientsRecruitingNCT02555371Phase 3
15Mepolizumab Treatment for Rhinovirus-induced Asthma ExacerbationsRecruitingNCT01520051Phase 3
16Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.RecruitingNCT02563067Phase 3
17Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.RecruitingNCT02555683Phase 3
18Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma ControlActive, not recruitingNCT02281318Phase 3
19A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic SubjectsActive, not recruitingNCT02135692Phase 3
20Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic AsthmaEnrolling by invitationNCT02559791Phase 2, Phase 3
21Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaTerminatedNCT01290887Phase 3
22A Phase IIa Study of KHK4563CompletedNCT01412736Phase 2
23Efficacy, Safety, and Tolerability of SAR231893 (REGN668) in Patients With Persistent Moderate to Severe Eosinophilic AsthmaCompletedNCT01312961Phase 2
24A Study to Evaluate the Effectiveness of a Drug (MEDI-563) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01227278Phase 2
25Anti-Interleukin-5 Antibody to Treat Hypereosinophilic SyndromeCompletedNCT00017862Phase 2
26Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent AsthmaCompletedNCT01545726Phase 2
27Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)CompletedNCT00086658Phase 2
28OC000459 Bronchial Allergen ChallengeCompletedNCT01056692Phase 2
29Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic SubjectsCompletedNCT01057927Phase 2
30Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
31Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in ChildrenRecruitingNCT02377427Phase 2
32Effect of OC459 on the Response to Rhinovirus Challenge in AsthmaRecruitingNCT02660489Phase 2
33Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic SyndromeRecruitingNCT02101138Phase 2
34Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic SyndromeRecruitingNCT02130882Phase 2
35Investigation of Lung Ventilation Inhomogeneity in Pediatric AsthmaActive, not recruitingNCT01095354Phase 2
36Effect of OC000459 on Eosinophilic Airway Inflammation in Severe AsthmaNot yet recruitingNCT02560610Phase 2
37Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol SupplementsCompletedNCT00466596Phase 1
38Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
39Sirolimus for Eosinophil-Associated Gastrointestinal DisordersTerminatedNCT01814059Phase 1
40Modification of Asthma With Soy IsoflavoneCompletedNCT00741208
41Activation and Function of Eosinophils in Conditions With Blood or Tissue EosinophiliaRecruitingNCT00001406
42Functional Activity of Airway Eosinophils in Allergic DiseaseRecruitingNCT01026532
43A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease ProgressionRecruitingNCT00091871
44The Factors Associated With the Formation of Nasal polyp-a Case Control and Descriptive StudyRecruitingNCT01278719
45Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT02760238
46Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial PneumoniaActive, not recruitingNCT01152424
47Use of a Probiotic Supplement to Prevent Asthma in InfantsActive, not recruitingNCT00113659
48Clinico-biological Correlation of Severe Asthma in ChildrenActive, not recruitingNCT02038374
49Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss SyndromeNot yet recruitingNCT02728271Phase 0
50Early Antiinflammatory Treatment of AsthmaTerminatedNCT00567463

Search NIH Clinical Center for Pulmonary Eosinophilia

Genetic Tests for Pulmonary Eosinophilia

About this section

Anatomical Context for Pulmonary Eosinophilia

About this section

MalaCards organs/tissues related to Pulmonary Eosinophilia:

33
Lung, T cells, Breast, Heart, Endothelial, Liver, Monocytes

Animal Models for Pulmonary Eosinophilia or affiliated genes

About this section

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053886.7CCL11, CCR3, CSF2, CYSLTR1, IL13, IL4
2MP:00053976.6CCL11, CCR3, CSF2, EPX, IL13, IL4
3MP:00053875.8CCL11, CCR3, CSF2, CYSLTR1, EPX, IL13

Publications for Pulmonary Eosinophilia

About this section

Articles related to Pulmonary Eosinophilia:

(show top 50)    (show all 284)
idTitleAuthorsYear
1
Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. (27215611)
2016
2
Genetic variants in interleukin genes and susceptibility to IgA nephropathy: a meta-analysis. (24592969)
2014
3
Sleepiness and Performance Is Disproportionate in Patients with Non-Organic Hypersomnia in Comparison to Patients with Narcolepsy and Mild to Moderate Obstructive Sleep Apnoea. (25377356)
2014
4
Constipation associated with brumation? Intestinal obstruction caused by a fecalith in a wild red diamond rattlesnake (Crotalus ruber). (23398054)
2014
5
Temperamental characteristics in childhood migraine without aura: a multicenter study. (23983467)
2013
6
Colonic intussusception caused by anisakiasis: a case report and review of the literature. (23318852)
2013
7
OBATOCLAX and ABT-737 Induce ER Stress Responses in Human Melanoma Cells that Limit Induction of Apoptosis. (24367627)
2013
8
Coronary artery ectasia and inflammatory cytokines: link with a predominant Th-2 immune response? (23742784)
2013
9
Quantitative EEG and apolipoprotein E-genotype improve classification of patients with suspected Alzheimer's disease. (23786792)
2013
10
Postpartum depression: is mode of delivery a risk factor? (23304542)
2012
11
A Unique Manifestation of Pupillary Fatigue in Autoimmune Autonomic Ganglionopathy. (22232207)
2012
12
Everolimus tablets for patients with subependymal giant cell astrocytoma. (21806479)
2011
13
Wild-type and brachyolmia-causing mutant TRPV4 channels respond directly to stretch force. (20605796)
2010
14
Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. (20849637)
2010
15
Sentinel surveillance of rectal chlamydia and gonorrhea among males--San Francisco, 2005-2008. (20118677)
2010
16
Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions. (20926562)
2010
17
Regulatory T cells as targets for immunotherapy of autoimmunity and inflammation. (19075787)
2008
18
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. (18402529)
2008
19
Abnormal nuclear factor (NF)-kappaB signal pathway and aspirin inhibits tumor necrosis factor alpha-induced NF-kappaB activation in keloid fibroblasts. (17550447)
2007
20
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. (17414625)
2007
21
Use of PLGA scaffold for mucociliary epithelium transfer in airway reconstruction: a preliminary study. (16720443)
2006
22
The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. (16288379)
2005
23
Studies of relationships between variation of the human G protein-coupled receptor 40 Gene and Type 2 diabetes and insulin release. (15606695)
2005
24
Neonatal diabetes mellitus: patient reports and review of current knowledge and clinical practice. (16459456)
2005
25
Pediatric tick paralysis: discussion of two cases and literature review. (15464647)
2004
26
Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. (14685796)
2004
27
The human protein Hugl-1 substitutes for Drosophila lethal giant larvae tumour suppressor function in vivo. (15467749)
2004
28
Retinoic acid enhances the gene expression of human polymeric immunoglobulin receptor (pIgR) by TNF-alpha. (15008977)
2004
29
Pharmacologic treatment of acute renal failure in sepsis. (14639066)
2003
30
Molecular pathogenesis of lipoid adrenal hyperplasia and adrenal hypoplasia congenita. (12943739)
2003
31
Cirrhosis and bleeding: the need for very early management. (12971959)
2003
32
Ulnar/fibular ray defect and brachydactyly in a family: a possible new autosomal dominant syndrome. (14564152)
2003
33
Activation of circulating platelets and platelet response to activating agents in children with cyanotic congenital heart disease: their relevance to palliative systemic-pulmonary shunt. (11399341)
2001
34
Luteinizing hormone receptors are self-associated in the plasma membrane. (11108263)
2000
35
Transcriptional dysregulation in Huntington's disease. (10941183)
2000
36
High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. (9573255)
1998
37
Chronic paroxysmal hemicrania presenting as otalgia with a sensation of external acoustic meatus obstruction: two cases and a pathophysiologic hypothesis. (11279905)
1998
38
VIP induces the translocation and degradation of the alpha subunit of Gs protein in rat pituitary GH4C1 cells. (9603988)
1998
39
Structure of diisopropyl fluorophosphate-inhibited factor D. (15299948)
1997
40
Cardiac sympathetic nerve function in congestive heart failure. (8653872)
1996
41
High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. (8607232)
1996
42
Endocarditis associated with infectious discitis. (8938877)
1996
43
Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. (8859000)
1996
44
Establishment and characterization of a human tongue cancer xenograft line in nude mice. (8935069)
1994
45
Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. (8231786)
1993
46
Study on in vitro invasive potential of renal cell carcinoma cell lines and effect of growth factors (EGF and TGF-beta 1) on their in invasions]. (2051699)
1991
47
Urethritis caused by neisseria meningitidis: a case report. (1783066)
1991
48
Unilateral linear basal cell nevus associated with diffuse osteoma cutis, unilateral anodontia, and abnormal bone mineralization. (2715453)
1989
49
Histogenesis of pseudomyxoma peritonei. Review of 9 cases. (840463)
1977
50
Surgery of ulnar neuropathy at the elbow: 16 cases treated by decompression without transposition. Technical note. (4710660)
1973

Variations for Pulmonary Eosinophilia

About this section

Expression for genes affiliated with Pulmonary Eosinophilia

About this section
Search GEO for disease gene expression data for Pulmonary Eosinophilia.

Pathways for genes affiliated with Pulmonary Eosinophilia

About this section

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 28)
idSuper pathwaysScoreTop Affiliating Genes
19.8CCL11, RNASE3
29.8IL4, IL5
39.7EPX, RNASE3
4
Show member pathways
9.5IL13, IL5, RNASE3
59.4CCL11, IL4, IL5
6
Show member pathways
9.4CCL11, IL4, RNASE3
7
Show member pathways
9.4IL13, IL4, IL5
89.4IL13, IL4, IL5
99.4IL13, IL4, IL5
109.4IL13, IL4, IL5
11
Show member pathways
9.2CSF2, IL4, IL5
12
Show member pathways
9.1CCL11, IL4, SFTPD
139.0CCL11, IL13, IL4, IL5
149.0CSF2, RNASE3, SFTPD
15
Show member pathways
9.0CCL11, CCR3, RNASE3
16
Show member pathways
8.9CCL11, CCR3, RNASE3
178.9CSF2, IL13, IL4, IL5
188.9CSF2, IL13, IL4, IL5
198.8CSF2, EPX, IL4, IL5
20
Show member pathways
8.5CSF2, IL13, IL4, IL5, RNASE3
21
Show member pathways
8.3CCL11, EPX, IL13, IL4, IL5, RNASE3
22
Show member pathways
8.3CCL11, EPX, IL13, IL4, IL5, RNASE3
23
Show member pathways
8.1CSF2, EPX, IL13, IL4, IL5, RNASE3
248.0CCR3, CSF2, EPX, IL4, IL5
25
Show member pathways
7.7CCL11, CCR3, CSF2, IL13, IL4, IL5
26
Show member pathways
7.4CCL11, CCR3, CSF2, IL13, IL4, IL5
27
Show member pathways
7.4CCL11, CCR3, CSF2, IL13, IL4, IL5
28
Show member pathways
6.9CCL11, CCR3, CSF2, EPX, IL13, IL4

GO Terms for genes affiliated with Pulmonary Eosinophilia

About this section

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of complement-dependent cytotoxicityGO:190366010.4IL13, IL4
2regulation of proton transportGO:001015510.3IL13, IL4
3positive regulation of mast cell degranulationGO:004330610.3IL13, IL4
4positive regulation of immunoglobulin productionGO:000263910.2IL13, IL4
5positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.1CSF2, IL4
6microglial cell activationGO:000177410.1IL13, IL4
7myeloid dendritic cell differentiationGO:004301110.0CSF2, IL4
8dendritic cell differentiationGO:009702810.0CSF2, IL4
9positive regulation of B cell proliferationGO:00308909.9IL13, IL4, IL5
10positive regulation of endothelial cell proliferationGO:00019389.7CCL11, CCR3
11chemokine-mediated signaling pathwayGO:00700989.4CCL11, CCR3
12positive regulation of GTPase activityGO:00435479.3CCL11, CSF2, IL5
13positive regulation of cell proliferationGO:00082849.2CSF2, IL4, IL5
14immune responseGO:00069558.2CCL11, CSF2, IL13, IL4, IL5

Sources for Pulmonary Eosinophilia

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet